| الوصف: |
Shun Lu,1 Wei Li,2 Caicun Zhou,3 Cheng-Ping Hu,4 Shukui Qin,5 Gang Cheng,6 Jifeng Feng,7 Jie Wang,8,9 Agnieszka Cseh,10 Barbara Peil,11 Neil Gibson,12 Eva Ehrnrooth,13 Li Zhang14 1Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China; 2Cancer Center, First Hospital of Jilin University, Changchun, China; 3Department of Oncology, Shanghai Pulmonary Hospital, Shanghai, China; 4Department of Respiratory Medicine, Xiangya Hospital, Central South University, Changsha, Hunan, China; 5People’s Liberation Army Cancer Center, Nanjing Bayi Hospital, Nanjing, Jiangsu, China; 6Department of Medical Oncology, Beijing Hospital, National Center of Gerontology, Beijing, China; 7Department of Internal Medicine, Jiangsu Provincial Tumor Hospital, Nanjing, China; 8Department of Internal Medicine, Capital Medical University, Beijing, China; 9Peking University School of Oncology, Beijing Cancer Hospital, Beijing, China; 10Department of Medical Affairs, Boehringer Ingelheim RCV GmbH & Co. KG, Vienna, Austria; 11Biostatistics, Boehringer Ingelheim Pharma GmbH & Co. KG. Ingelheim, Germany; 12Translational Medicine and Clinical Oncology, Boehringer Ingelheim Pharma GmbH & Co. KG. Biberach, Germany; 13Division of Oncology, Boehringer Ingelheim, Danmark A/S, Copenhagen, Denmark; 14Department of Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China Background: The global Phase III LUX-Lung 8 trial (ClinicalTrials.gov: NCT01523587) identified significant improvements in progression-free survival (PFS), overall survival (OS), and patient-reported outcomes (PROs) with second-line afatinib vs erlotinib in patients with advanced squamous cell carcinoma (SCC) of the lung. Materials and methods: We conducted a post hoc analysis of data for patients in LUX-Lung 8 from mainland China (n=67). Compared with erlotinib, afatinib reduced the risk of disease progression or death (PFS) in the Chinese subgroup by 30% (HR=0.70; 95% CI: 0.38–1.27). Results: The risk of death was ... |